World Journal of Diabetes,
Journal Year:
2023,
Volume and Issue:
14(4), P. 396 - 411
Published: April 11, 2023
The
global
prevalence
of
obesity
is
increasing
rapidly
with
an
exponential
rise
in
incidence
type
2
diabetes
mellitus
recent
years.
'Diabesity',
the
term
coined
to
show
strong
interlink
between
and
diabetes,
direct
cons-equence
pandemic,
poses
significant
challenges
management
disease.
Without
addressing
clinical
mechanistic
complications
such
as
metabolic-associated
fatty
liver
disease
obstructive
sleep
apnoea,
a
rational
algorithm
for
diabesity
cannot
be
developed.
Several
classes
anti-diabetic
medications
including
insulins,
sulphonylureas,
thiazolidinediones
meglitinides
are
associated
risk
weight
gain
may
potentially
worsen
diabesity.
Therefore,
appropriate
selection
antidiabetic
drug
regimen
crucial
medical
role
non-pharmacological
measures
dietary
adjustments,
exercise
interventions
bariatric
procedures
should
also
emphasised.
Unfortunately,
importance
optimal
often
overlooked
by
professionals
when
achieving
adequate
glycemic
control
which
results
inappropriate
its
complications.
This
review
provides
narrative
update
on
evidence
behind
European Heart Journal,
Journal Year:
2019,
Volume and Issue:
41(1), P. 111 - 188
Published: Aug. 31, 2019
The
ESC/EAS
Guidelines
represent
the
views
of
ESC
and
EAS,
were
produced
after
careful
consideration
scientific
medical
knowledge,
evidence
available
at
time
their
publication.The
EAS
is
not
responsible
in
event
any
contradiction,
discrepancy,
and/or
ambiguity
between
other
official
recommendations
or
guidelines
issued
by
relevant
public
health
authorities,
particular
relation
to
good
use
healthcare
therapeutic
strategies.Health
professionals
are
encouraged
take
fully
into
account
when
exercising
clinical
judgment,
as
well
determination
implementation
preventive,
diagnostic,
strategies;
however,
do
override,
way
whatsoever,
individual
responsibility
make
appropriate
accurate
decisions
each
patient's
condition
consultation
with
that
patient
and,
where
necessary,
caregiver.Nor
exempt
from
taking
full
updated
competent
order
manage
case
light
scientifically
accepted
data
pursuant
respective
ethical
professional
obligations.It
also
professional's
verify
applicable
rules
regulations
relating
drugs
devices
prescription.
Gut,
Journal Year:
2020,
Volume and Issue:
69(9), P. 1691 - 1705
Published: April 22, 2020
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
a
public
health
problem,
affecting
up
to
third
of
the
world's
adult
population.
Several
cohort
studies
have
consistently
documented
that
NAFLD
(especially
in
its
more
advanced
forms)
associated
with
higher
risk
all-cause
mortality
and
leading
causes
death
among
patients
are
cardiovascular
diseases
(CVDs),
followed
by
extrahepatic
malignancies
liver-related
complications.
A
growing
body
evidence
also
indicates
strongly
an
increased
major
CVD
events
other
cardiac
complications
(ie,
cardiomyopathy,
valvular
calcification
arrhythmias),
independently
traditional
factors.
This
narrative
review
provides
overview
literature
on:
(1)
for
association
between
cardiovascular,
arrhythmic
complications,
(2)
putative
pathophysiological
mechanisms
linking
(3)
current
pharmacological
treatments
might
benefit
or
adversely
affect
CVD.
Gut,
Journal Year:
2020,
Volume and Issue:
70(5), P. 962 - 969
Published: Sept. 16, 2020
Objective
Follow-up
studies
have
shown
that
non-alcoholic
fatty
liver
disease
(NAFLD)
is
associated
with
an
increased
risk
of
incident
diabetes,
but
currently,
it
uncertain
whether
this
changes
increasing
severity
NAFLD.
We
performed
a
meta-analysis
relevant
to
quantify
the
magnitude
association
between
NAFLD
and
diabetes.
Design
systematically
searched
PubMed,
Scopus
Web
Science
databases
from
January
2000
June
2020
using
predefined
keywords
identify
observational
follow-up
duration
at
least
1
year,
in
which
was
diagnosed
by
imaging
techniques
or
biopsy.
Meta-analysis
random-effects
modelling.
Results
33
501
022
individuals
(30.8%
NAFLD)
27
953
cases
diabetes
over
median
5
years
(IQR:
4.0–19
years)
were
included.
Patients
had
higher
than
those
without
(n=26
studies;
HR
2.19,
95%
CI
1.93
2.48;
I
2
=91.2%).
more
‘severe’
also
likely
develop
(n=9
2.69,
2.08
3.49;
=69%).
This
markedly
across
fibrosis
(n=5
3.42,
2.29
5.11;
=44.6%).
All
risks
independent
age,
sex,
adiposity
measures
other
common
metabolic
factors.
Sensitivity
analyses
did
not
alter
these
findings.
Funnel
plots
reveal
any
significant
publication
bias.
Conclusion
updated
shows
~2.2-fold
parallels
underlying
International Journal of Molecular Sciences,
Journal Year:
2021,
Volume and Issue:
22(8), P. 4156 - 4156
Published: April 16, 2021
Many
studies
have
reported
that
metabolic
dysfunction
is
closely
involved
in
the
complex
mechanism
underlying
development
of
non-alcoholic
fatty
liver
disease
(NAFLD),
which
has
prompted
a
movement
to
consider
renaming
NAFLD
as
dysfunction-associated
(MAFLD).
Metabolic
this
context
encompasses
obesity,
type
2
diabetes
mellitus,
hypertension,
dyslipidemia,
and
syndrome,
with
insulin
resistance
common
pathophysiology.
Imbalance
between
energy
intake
expenditure
results
various
tissues
alteration
gut
microbiota,
resulting
fat
accumulation
liver.
The
role
genetics
also
been
revealed
hepatic
fibrosis.
In
process
liver,
intracellular
damage
well
further
potentiates
inflammation,
fibrosis,
carcinogenesis.
Increased
lipogenic
substrate
supply
from
other
tissues,
zonation
Irs1,
factors,
including
ER
stress,
play
crucial
roles
increased
de
novo
lipogenesis
MAFLD
resistance.
Herein,
we
provide
an
overview
factors
contributing
systemic
local
progression
MAFLD.